An Efficient Combination Therapy with Lisdexamfetamine Dimesylate and Topiramate in Improving Binge Eating Scale & Metabolic Profile in Binge Eating Disorder: A Randomized Control Trial
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Comprehensive evaluation of lisedexamfetamine dimesylate (LDX) alone and in combination with topiramate (TPM) was done for treatment of binge eating disorder (BED) in adults aged 18−55 years. Methods: In the present randomized clinical trial study, 93 patients were selected by convenience sampling method and were allocated to two groups of 48 and 45 using the permuted block randomization method. This study was conducted from January to September 2022 in Shiraz, Iran. Patients received LDX (n = 48) or LDX plus TPM. Average dose of LDX was 37.5 mg/day and 38 mg/day in the first and second group respectively. The second group (n = 45) also received TPM with average dose of 77.7 mg/day. Results: Twelve weeks treatment caused significant higher mean reduction in level of triglyceride (73.68 vs. 58.97 respectively, p = 0.024), low density lipo-protein (LDL) (9.66 vs. 5.16 respectively, p ＜ 0.001) and body mass index (5.48 vs. 3.41 respectively, p ＜ 0.001) with TPM plus LDX and also greater significant improvement (p ＜ 0.001) in binge eating scale compared to use of LDX alone. Combination therapy with TPM and LDX had better tolerability and lower adverse events such as insomnia (p ＜ 0.001), paresthesia (p = 0.001), confusion (p = 0.035) and ataxia (p = 0.009) compared to monotherapy in BED. Conclusion: The combinative treatment was more effective than single drug in terms of higher tolerability, safety and causing lesser adverse events for BED patients. However, more studies with larger samples are needed
Abstract
Objective: Comprehensive evaluation of lisedexamfetamine dimesylate (LDX) alone and in combination with topiramate (TPM) was done for treatment of binge eating disorder (BED) in adults aged 18−55 years. Methods: In the present randomized clinical trial study, 93 patients were selected by convenience sampling method and were allocated to two groups of 48 and 45 using the permuted block randomization method. This study was conducted from January to September 2022 in Shiraz, Iran. Patients received LDX (n = 48) or LDX plus TPM. Average dose of LDX was 37.5 mg/day and 38 mg/day in the first and second group respectively. The second group (n = 45) also received TPM with average dose of 77.7 mg/day. Results: Twelve weeks treatment caused significant higher mean reduction in level of triglyceride (73.68 vs. 58.97 respectively, p = 0.024), low density lipo-protein (LDL) (9.66 vs. 5.16 respectively, p ＜ 0.001) and body mass index (5.48 vs. 3.41 respectively, p ＜ 0.001) with TPM plus LDX and also greater significant improvement (p ＜ 0.001) in binge eating scale compared to use of LDX alone. Combination therapy with TPM and LDX had better tolerability and lower adverse events such as insomnia (p ＜ 0.001), paresthesia (p = 0.001), confusion (p = 0.035) and ataxia (p = 0.009) compared to monotherapy in BED. Conclusion: The combinative treatment was more effective than single drug in terms of higher tolerability, safety and causing lesser adverse events for BED patients. However, more studies with larger samples are needed
참고문헌 (35)
- Appolinario JC, "Correlates and impact of DSM-5 binge eating disorder, bulimia nervosa and recurrent binge eating : a representative population survey in a middle-income country", Soc Psychiatry Psychiatr Epidemiol, 57, pp.1491~1503 (2022)
- Citrome L, "Binge eating disorder : a psychiatrist’s commentary on clinical considerations", Clin Ther, 43, pp.7~16 (2021)
- Hilbert A, "Meta-analysis on the long-term effectiveness of psychological and medical treatments for binge-eating disorder", Int J Eat Disord, 53, pp.1353~1376 (2020)
- Hauck C, "Food addiction, eating addiction and eating disorders", Proc Nutr Soc, 79, pp.103~112 (2020)
- McElroy SL, "Pharmacologic treatments for binge-eating disorder", J Clin Psychiatry, 78(Suppl 1), pp.14~19 (2017)
- Amodeo G, "Pharmacotherapeutic strategies for treating binge eating disorder. Evidence from clinical trials and implications for clinical practice", Expert Opin Pharmacother, 20, pp.679~690 (2019)
- Levitan MN, "Binge eating disorder : a 5-year retrospective study on experimental drugs", J Exp Pharmacol, 13, pp.33~47 (2021)
- Pipe A, "Binge eating disorder hidden behind a wall of anxiety disorders", J Psychiatry Neurosci, 46, pp.E208~E209 (2021)
- Fala L, "Seventh annual payers’ guide" (2016), American Health & Drug Benefits
- Keski-Rahkonen A, "Epidemiology of binge eating disorder : prevalence, course, comorbidity, and risk factors", Curr Opin Psychiatry, 34, pp.525~531 (2021)
- Davis HA, "Overview of binge eating disorder", Curr Cardiovasc Risk Rep, 14, pp.26~ (2020)
- Griffiths KR, "Understanding the neural mechanisms of lisdexamfetamine dimesylate(LDX)pharmacotherapy in Binge Eating Disorder(BED) : a study protocol", J Eat Disord, 7, pp.23~ (2019)
- Boswell RG, "The neurobiology of binge-eating disorder compared with obesity : implications for differential therapeutics", Clin Ther, 43, pp.50~69 (2021)
- Griffiths KR, "Impulsivity and its relationship with lisdexamfetamine dimesylate treatment in binge eating disorder", Front Psychol, 12, pp.716010~ (2021)
- Veeraraghavan V, "Obesogenic behavior and binge eating disorder in an elderly female with schizophrenia", J Obes Metab Syndr, 30, pp.184~187 (2021)
- Kalaria SN, "An innovative disease-drug-trial framework to guide binge eating disorder drug development : a case study for topiramate", Clin Transl Sci, 13, pp.88~97 (2020)
- Reas DL, "Current and emerging drug treatments for binge eating disorder", Expert Opin Emerg Drugs, 19, pp.99~142 (2014)
- Nourredine M, "Efficacy and safety of topiramate in binge eating disorder : a systematic review and meta-analysis", CNS Spectr, 26, pp.459~467 (2021)
- Gormally J, "The assessment of binge eating severity among obese persons", Addict Behav, 7, pp.47~55 (1982)
- Mootabi F, "Standardization of the binge eating scale among Iranian obese population", Iran J Psychiatry, 4, pp.143~146 (2009)
- Mousavi Asl E, "Beliefs about binge eating : the psychometric properties of the Persian version of the eating beliefs questionnaire", J Res Med Sci, 25, pp.73~ (2020)
- Asl EM, "Eating disorders screening tools : the psychometric properties of the persian version of eating attitude test", Int J Prev Med, 12, pp.122~ (2021)
- Heal DJ, "Prospects for new drugs to treat binge-eating disorder : insights from psychopathology and neuropharmacology", J Psychopharmacol, 36, pp.680~703 (2022)
- Chapron SA, "Efficacy and safety of topiramate for reducing impulsivity : a transdiagnostic systematic review and meta-analysis of a common clinical use", Fundam Clin Pharmacol, 36, pp.4~15 (2022)
- McElroy SL, "Topiramate in the treatment of binge eating disorder associated with obesity : a randomized, placebo-controlled trial", Am J Psychiatry, 160, pp.255~261 (2003)
- McElroy SL, "Topiramate in the long-term treatment of binge-eating disorder associated with obesity", J Clin Psychiatry, 65, pp.1463~1469 (2004)
- McElroy SL, "Topiramate for the treatment of binge eating disorder associated with obesity : a placebo-controlled study", Biol Psychiatry, 61, pp.1039~1048 (2007)
- Brambilla F, "Multivariate therapeutic approach to binge-eating disorder : combined nutritional, psychological and pharmacological treatment", Int Clin Psychopharmacol, 24, pp.312~317 (2009)
- Claudino AM, "Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder", J Clin Psychiatry, 68, pp.1324~1332 (2007)
- Guerdjikova AI, "Combination phentermine-topiramate extended release for the treatment of binge eating disorder : an open-label, prospective study", Innov Clin Neurosci, 15, pp.17~21 (2018)
- Nourredine M, "Use of topiramate in the spectrum of addictive and eating disorders : a systematic review comparing treatment schemes, efficacy, and safety features", CNS Drugs, 35, pp.177~213 (2021)
- Yu Y, "A literature review of dopamine in binge eating", J Eat Disord, 10, pp.11~ (2022)
- Schneider E, "The effects of lisdexamfetamine dimesylate on eating behaviour and homeostatic, reward and cognitive processes in women with binge-eating symptoms : an experimental medicine study", Transl Psychiatry, 12, pp.9~ (2022)
- Ermer J, "A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects", Neuropsychopharmacol Rep, 40, pp.16~29 (2020)
- Guerdjikova AI, "Lisdexamfetamine dimesylate in binge eating disorder : a placebo controlled trial", Hum Psychopharmacol, 31, pp.382~391 (2016)